AstraZeneca still considers a vaccine possible this year

Coronavirus: Who will win the vaccine race?

-

The British pharmaceutical group AstraZeneca judged Thursday still possible to have a vaccine against Covid-19 available by the end of the year, despite the pause in the trials of its project carried out with the University of Oxford.

During an online conference organized by the media group Tortoise, the head of the laboratory explained, however, that the decision to resume testing was not the responsibility of his group but of a committee of independent experts.

During this conference, the French leader reiterated that such a pause in trials was not abnormal, but that it had more resonance given the interest around this vaccine, considered one of the most promising to the world.

WHO lists 35 "vaccine candidates"

The bracketing of the trials was decided after the onset of a "potentially unexplained illness", possibly a serious side effect, in a participant in the UK.

The vaccine developed by AstraZeneca and the British University of Oxford is one of the most advanced Western projects, tested on tens of thousands of volunteers in the United Kingdom, Brazil, South Africa and, since August 31, the United States, in what is called phase 3 of the trials, the last, to verify safety and efficacy.

In its last point dated Wednesday, the WHO lists 35 “vaccine candidates” evaluated in clinical trials on humans around the world.

Nine are already at the last stage, or are preparing to enter.

The European Medicines Agency (EMA) estimates "that it could take at least until early 2021 for a vaccine against Covid-19 to be ready for approval and available in sufficient quantities" for global use.

Society

Coronavirus: Who will be responsible in the event of side effects from a Covid-19 vaccine?

Health

Coronavirus: Trials launched, schedule ... Where is the race for vaccines?

• Laboratory

• Research

• Vaccine

• Covid 19

• Coronavirus

• Health